Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Jay k. who wrote (75794)	6/7/2002 7:33:28 AM
From: Jay k.	Respond to of 99280

BGEN was trading at 44 earlier now trading around 40... When it rains it pours. NEW YORK, June 7 (Reuters) - Biogen Inc. (NasdaqNM:BGEN - News) on Friday said its earnings for the second quarter and full year will be lower than expected amid slower sales of its flagship multiple sclerosis drug Avonex. Biogen, based in Cambridge, Massachusetts, said it expects sales of Avonex to be between $170 million and $180 million in the second quarter, about $20 million less than previously forecast. The decline in Avonex sales will cut its earnings by 9 cents a share for the second quarter, to between 28 cents and 32 cents a share, the company said. Analysts had expected earnings of 40 cents a share, down from 47 cents a year earlier, according to Thomson First Call. For the full year, the company said it expects Avonex revenue of $730 million to $755 million. The company said in April it expected 2002 Avonex sales of $1.1 billion, and royalties of $75 million to $85 million. The company said it expects operating earnings for the full year of $1.50 to $1.60 per share. Analysts had expected $1.72 a share, down from $1.90 in 2001 biz.yahoo.com